Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2019

Open Access 01-12-2019 | Strabismus | Research

Ocular manifestations in Gorlin-Goltz syndrome

Authors: Antonietta Moramarco, Ehud Himmelblau, Emanuele Miraglia, Fabiana Mallone, Vincenzo Roberti, Federica Franzone, Chiara Iacovino, Sandra Giustini, Alessandro Lambiase

Published in: Orphanet Journal of Rare Diseases | Issue 1/2019

Login to get access

Abstract

Background

Gorlin-Goltz syndrome, also known as nevoid basal cell carcinoma syndrome, is a rare genetic disorder that is transmitted in an autosomal dominant manner with complete penetrance and variable expressivity. It is caused in 85% of the cases with a known etiology by pathogenic variants in the PTCH1 gene, and is characterized by a wide range of developmental abnormalities and a predisposition to multiple neoplasms. The manifestations are multiple and systemic and consist of basal cell carcinomas in various regions, odontogenic keratocistic tumors and skeletal anomalies, to name the most frequent. Despite the scarce medical literature on the topic, ocular involvement in this syndrome is frequent and at the level of various ocular structures. Our study focuses on the visual apparatus and its annexes in subjects with this syndrome, in order to better understand how this syndrome affects the ocular system, and to evaluate with greater accuracy and precision the nature of these manifestations in this group of patients.

Results

Our study confirms the presence of the commonly cited ocular findings in the general literature regarding the syndrome [hypertelorism (45.5%), congenital cataract (18%), nystagmus (9%), colobomas (9%)] and highlights strabismus (63% of the patients), epiretinal membranes (36%) and myelinated optic nerve fiber layers (36%) as the most frequent ophthalmological findings in this group of patients.

Conclusions

The presence of characteristic and frequent ocular signs in the Gorlin- Goltz syndrome could help with the diagnostic process in subjects suspected of having the syndrome who do not yet have a diagnosis. The ophthalmologist has a role as part of a multidisciplinary team in managing these patients. The ophthalmological follow-up that these patients require, can allow, if necessary, a timely therapy that could improve the visual prognosis of such patients.
Literature
1.
go back to reference Farndon PA, Del Mastro RG, Evans DG, Kilpatrick MW. Location of gene for gorlin syndrome. Lancet. 1992;339:581–2.CrossRef Farndon PA, Del Mastro RG, Evans DG, Kilpatrick MW. Location of gene for gorlin syndrome. Lancet. 1992;339:581–2.CrossRef
2.
go back to reference Evans DG, Birch JM, Orton CI. Brain tumours and the occurrence of severe invasive basal cell carcinoma in first degree relatives with Gorlin syndrome. Br J Neurosurg. 1991;5:643–6.CrossRef Evans DG, Birch JM, Orton CI. Brain tumours and the occurrence of severe invasive basal cell carcinoma in first degree relatives with Gorlin syndrome. Br J Neurosurg. 1991;5:643–6.CrossRef
3.
go back to reference Pratt MD, Jackson R. Nevoid basal cell carcinoma syndrome. A 15-year follow-up of cases in Ottawa and the Ottawa Valley. J Am Acad Dermatol. 1987;16:964–70.CrossRef Pratt MD, Jackson R. Nevoid basal cell carcinoma syndrome. A 15-year follow-up of cases in Ottawa and the Ottawa Valley. J Am Acad Dermatol. 1987;16:964–70.CrossRef
4.
go back to reference Lo Muzio L, Nocini PF, Savoia A, Consolo U, Procaccini M, Zelante L, et al. Nevoid basal cell carcinoma syndrome. Clinical findings in 37 Italian affected individuals. Clin Genet. 1999;55:34–40.CrossRef Lo Muzio L, Nocini PF, Savoia A, Consolo U, Procaccini M, Zelante L, et al. Nevoid basal cell carcinoma syndrome. Clinical findings in 37 Italian affected individuals. Clin Genet. 1999;55:34–40.CrossRef
5.
go back to reference Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A(2):327–32.CrossRef Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A(2):327–32.CrossRef
6.
go back to reference Smith MJ, Beetz C, Williams SG, Bhaskar SS, O'Sullivan J, Anderson B, Daly SB, Urquhart JE, Bholah Z, Oudit D, Cheesman E, Kelsey A, McCabe MG, Newman WG, Evans DG. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol. 2014;32:4155–61.CrossRef Smith MJ, Beetz C, Williams SG, Bhaskar SS, O'Sullivan J, Anderson B, Daly SB, Urquhart JE, Bholah Z, Oudit D, Cheesman E, Kelsey A, McCabe MG, Newman WG, Evans DG. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol. 2014;32:4155–61.CrossRef
7.
go back to reference Bholah Z, Smith MJ, Byers HJ, Miles EK, Evans DG, Newman WG. Intronic splicing mutations in PTCH1 cause Gorlin syndrome. Familial Cancer. 2014;13:477–80.CrossRef Bholah Z, Smith MJ, Byers HJ, Miles EK, Evans DG, Newman WG. Intronic splicing mutations in PTCH1 cause Gorlin syndrome. Familial Cancer. 2014;13:477–80.CrossRef
8.
go back to reference Evans DG, Oudit D, Smith MJ, Rutkowski D, Allan E, Newman WG, Lear JT. First evidence of genotype-phenotype correlations in Gorlin syndrome. J Med Genet. 2017;54:530–6.CrossRef Evans DG, Oudit D, Smith MJ, Rutkowski D, Allan E, Newman WG, Lear JT. First evidence of genotype-phenotype correlations in Gorlin syndrome. J Med Genet. 2017;54:530–6.CrossRef
9.
go back to reference Marigo V, Davey RA, Zuo Y, Cunningham JM, Tabin CJ. Biochemical evidence that Patched is the hedgehog receptor. Nature. 1996;384:176–9.CrossRef Marigo V, Davey RA, Zuo Y, Cunningham JM, Tabin CJ. Biochemical evidence that Patched is the hedgehog receptor. Nature. 1996;384:176–9.CrossRef
10.
go back to reference Adolphe C, Hetherington R, Ellis T, Wainwright B. Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res. 2006;66(4):2081–8.CrossRef Adolphe C, Hetherington R, Ellis T, Wainwright B. Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res. 2006;66(4):2081–8.CrossRef
11.
go back to reference Bale AE, Yu KP. The hedgehog pathway and basal cell carcinomas. Hum Mol Genet. 2001;10(7):757–62.CrossRef Bale AE, Yu KP. The hedgehog pathway and basal cell carcinomas. Hum Mol Genet. 2001;10(7):757–62.CrossRef
12.
go back to reference Lindström E, Shimokawa T, Toftgård R, Zaphiropoulos PG. PTCH mutations: distribution and analyses. Hum Mutat. 2006;27(3):215–9.CrossRef Lindström E, Shimokawa T, Toftgård R, Zaphiropoulos PG. PTCH mutations: distribution and analyses. Hum Mutat. 2006;27(3):215–9.CrossRef
13.
go back to reference Ling G, Ahmadian A, Persson A, Undén AB, Afink G, Williams C, Uhlén M, Toftgård R, Lundeberg J, Pontén F. PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene. 2001;20(53):7770–8.CrossRef Ling G, Ahmadian A, Persson A, Undén AB, Afink G, Williams C, Uhlén M, Toftgård R, Lundeberg J, Pontén F. PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene. 2001;20(53):7770–8.CrossRef
14.
go back to reference Molecular Location: base pairs 95,442,980 to 95,517,057 on chromosome 9 (Homo sapiens Annotation Release 109, GRCh38.p12). Molecular Location: base pairs 95,442,980 to 95,517,057 on chromosome 9 (Homo sapiens Annotation Release 109, GRCh38.p12).
15.
go back to reference Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, Scott MP, Beachy PA. Effects of oncogenic mutations in smoothened and Patched can be reversed by cyclopamine. Nature. 2000;406:1005–9.CrossRef Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, Scott MP, Beachy PA. Effects of oncogenic mutations in smoothened and Patched can be reversed by cyclopamine. Nature. 2000;406:1005–9.CrossRef
16.
go back to reference Levanat S, Gorlin RJ, Fallet S, Johnson DR, Fantasia JE, Bale AE. A two-hit model for developmental defects in Gorlin syndrome. Nat Genet. 1996;12(1):85–7.CrossRef Levanat S, Gorlin RJ, Fallet S, Johnson DR, Fantasia JE, Bale AE. A two-hit model for developmental defects in Gorlin syndrome. Nat Genet. 1996;12(1):85–7.CrossRef
17.
go back to reference Cherry AL, Finta C, Karlström M, Jin Q, Schwend T, Astorga-Wells J, et al. tructural basis of SUFU-GLI interaction in human hedgehog signalling regulation. Acta Crystallogr Sect D Biol Crystallogr. 2013;69:2563–79.CrossRef Cherry AL, Finta C, Karlström M, Jin Q, Schwend T, Astorga-Wells J, et al. tructural basis of SUFU-GLI interaction in human hedgehog signalling regulation. Acta Crystallogr Sect D Biol Crystallogr. 2013;69:2563–79.CrossRef
18.
go back to reference Fujii K, Ohashi H, Suzuki M, Hatsuse H, Shiohama T, Uchikawa H, Miyashita T. Frameshift mutation in the PTCH2 gene can cause nevoid basal cell carcinoma syndrome. Familial Cancer. 2013;12:611–4.CrossRef Fujii K, Ohashi H, Suzuki M, Hatsuse H, Shiohama T, Uchikawa H, Miyashita T. Frameshift mutation in the PTCH2 gene can cause nevoid basal cell carcinoma syndrome. Familial Cancer. 2013;12:611–4.CrossRef
19.
go back to reference Soufir N, Gerard B, Portela M, Brice A, Liboutet M, Saiag P, et al. PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study. Br J Cancer. 2006;95:548–53.CrossRef Soufir N, Gerard B, Portela M, Brice A, Liboutet M, Saiag P, et al. PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study. Br J Cancer. 2006;95:548–53.CrossRef
20.
go back to reference Kimonis VE, Mehta SG, Digiovanna JJ, Bale SJ, Pastakia B. Radiological features in 82 patients with nevoid basal cell carcinoma (NBCC or Gorlin) syndrome. Genet Med. 2004;6(6):495–502.CrossRef Kimonis VE, Mehta SG, Digiovanna JJ, Bale SJ, Pastakia B. Radiological features in 82 patients with nevoid basal cell carcinoma (NBCC or Gorlin) syndrome. Genet Med. 2004;6(6):495–502.CrossRef
21.
go back to reference Ahn SG, Lim YS, Kim DK, Kim SG, Lee SH, Yoon JH. Nevoid basal cell carcinoma syndrome: a retrospective analysis of 33 affected Korean individuals. Int J Oral Maxillofac Surg. 2004;33:458–62.CrossRef Ahn SG, Lim YS, Kim DK, Kim SG, Lee SH, Yoon JH. Nevoid basal cell carcinoma syndrome: a retrospective analysis of 33 affected Korean individuals. Int J Oral Maxillofac Surg. 2004;33:458–62.CrossRef
22.
go back to reference Endo M, Fujii K, Sugita K, Saito K, Kohno Y, Miyashita T. Nationwide survey of nevoid basal cell carcinoma syndrome in Japan revealing the low frequency of basal cell carcinoma. Am J Med Genet A. 2012;158A:351–7.CrossRef Endo M, Fujii K, Sugita K, Saito K, Kohno Y, Miyashita T. Nationwide survey of nevoid basal cell carcinoma syndrome in Japan revealing the low frequency of basal cell carcinoma. Am J Med Genet A. 2012;158A:351–7.CrossRef
23.
go back to reference Evans DG, Ladusans EJ, Rimmer S, Burnell LD, Thakker N, Farndon PA. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet. 1993;30:460–4.CrossRef Evans DG, Ladusans EJ, Rimmer S, Burnell LD, Thakker N, Farndon PA. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet. 1993;30:460–4.CrossRef
24.
go back to reference Muzio Lorenzo Lo. Orphanet Encyclopedia. 2002. pp. 166–69. Muzio Lorenzo Lo. Orphanet Encyclopedia. 2002. pp. 166–69.
25.
go back to reference Shanley S, Ratcliffe J, Hockey A, et al. Nevoid basal cell carcinoma syndrome: review of 118 affected individuals. Am J Med Genet. 1994;50:282–90.CrossRef Shanley S, Ratcliffe J, Hockey A, et al. Nevoid basal cell carcinoma syndrome: review of 118 affected individuals. Am J Med Genet. 1994;50:282–90.CrossRef
26.
go back to reference Black GC, Mazerolle CJ, Wang Y, Campsall KD, Petrin D, Leonard BC, Damji KF, Evans DG, McLeod D, Wallace VA. Abnormalities of the vitreoretinal interface caused by dysregulated hedgehog signaling during retinal development. Hum Mol Genet. 2003;12(24):3269–76.CrossRef Black GC, Mazerolle CJ, Wang Y, Campsall KD, Petrin D, Leonard BC, Damji KF, Evans DG, McLeod D, Wallace VA. Abnormalities of the vitreoretinal interface caused by dysregulated hedgehog signaling during retinal development. Hum Mol Genet. 2003;12(24):3269–76.CrossRef
27.
go back to reference Taylor SF, Cook AE, Leatherbarrow B. review of patients with basal cell nevus syndrome.Ophthalmic plastic and reconstructive surgery. 2006;22(4):259–265. Taylor SF, Cook AE, Leatherbarrow B. review of patients with basal cell nevus syndrome.Ophthalmic plastic and reconstructive surgery. 2006;22(4):259–265.
28.
go back to reference De Jong PT, Bistervels B, Cosgrove J, de Grip G, Leys A, Goffin M. Medullated nerve fibers. A sign of multiple basal cell nevi (Gorlin's) syndrome. Arch Ophthalmol. 1985;103:1833–6.CrossRef De Jong PT, Bistervels B, Cosgrove J, de Grip G, Leys A, Goffin M. Medullated nerve fibers. A sign of multiple basal cell nevi (Gorlin's) syndrome. Arch Ophthalmol. 1985;103:1833–6.CrossRef
29.
go back to reference Kodama T, Hayasaka S, Setogawa T. Myelinated retinal nerve fibers: prevalence, location and effect on visual acuity. Ophthalmologica. 1990;200:77–83.CrossRef Kodama T, Hayasaka S, Setogawa T. Myelinated retinal nerve fibers: prevalence, location and effect on visual acuity. Ophthalmologica. 1990;200:77–83.CrossRef
30.
go back to reference Fraser-Bell S, Guzowski M, Rochtchina E, et al. Five-year cumulative incidence and progression of epiretinal membranes: the Blue Mountains eye study. Ophthalmology. 2003;110(1):34–40.CrossRef Fraser-Bell S, Guzowski M, Rochtchina E, et al. Five-year cumulative incidence and progression of epiretinal membranes: the Blue Mountains eye study. Ophthalmology. 2003;110(1):34–40.CrossRef
31.
go back to reference Salati C, Virgili G, Menchini U, Frattasio A, Patrone G. Gorlin's syndrome. Case report. Eur J Ophthalmol. 1997;7:113–4.CrossRef Salati C, Virgili G, Menchini U, Frattasio A, Patrone G. Gorlin's syndrome. Case report. Eur J Ophthalmol. 1997;7:113–4.CrossRef
32.
go back to reference Guercio JR, Martyn LJ. Congenital malformations of the eye and orbit. Otolaryngol Clin N Am. 2007;40(1):113–40 vii. Review.CrossRef Guercio JR, Martyn LJ. Congenital malformations of the eye and orbit. Otolaryngol Clin N Am. 2007;40(1):113–40 vii. Review.CrossRef
33.
go back to reference Tessier P. Orbital hypertelorism. I. Successive surgical attempts. Material and methods causes and mechanisms. Scand J Plast Reconstr Surg. 1972;6:135–55.CrossRef Tessier P. Orbital hypertelorism. I. Successive surgical attempts. Material and methods causes and mechanisms. Scand J Plast Reconstr Surg. 1972;6:135–55.CrossRef
34.
go back to reference Sühan T. The Irvine prism test: does the positive response indicate suppression scotoma? Int Ophthalmol. 2005;26:67–72. Sühan T. The Irvine prism test: does the positive response indicate suppression scotoma? Int Ophthalmol. 2005;26:67–72.
35.
go back to reference Rutstein RP, Cogen MS, Cotter SA, Daum KM, Mozlin RL, Ryan JM. Optometric clinical practice guideline care of the patient with strabismus: esotropia and exotripia. In: Reference guide for clinicians; 2005. p. 4. Rutstein RP, Cogen MS, Cotter SA, Daum KM, Mozlin RL, Ryan JM. Optometric clinical practice guideline care of the patient with strabismus: esotropia and exotripia. In: Reference guide for clinicians; 2005. p. 4.
36.
go back to reference Tranos P, Wickham L, Dervenis N, Vakalis A, Asteriades S, Stavrakas P. The role of membraneinner retina adherence in predicting simultaneous internal limiting membrane peeling during idiopathic epiretinal membrane surgery. Eye (Lond). 2017;31(4):636–42.CrossRef Tranos P, Wickham L, Dervenis N, Vakalis A, Asteriades S, Stavrakas P. The role of membraneinner retina adherence in predicting simultaneous internal limiting membrane peeling during idiopathic epiretinal membrane surgery. Eye (Lond). 2017;31(4):636–42.CrossRef
37.
go back to reference Friedman NJ, Kaiser PK. Essentials of ophthalmology. Philadelphia, PA: Elsevier Inc; 2007:253–254.CrossRef Friedman NJ, Kaiser PK. Essentials of ophthalmology. Philadelphia, PA: Elsevier Inc; 2007:253–254.CrossRef
39.
go back to reference Díaz-Valverde A, Wu L. To peel or not to peel the internal limiting membrane in idiopathic epiretinal membranes. Retina. 2018;38(Suppl 1):S5–S11.CrossRef Díaz-Valverde A, Wu L. To peel or not to peel the internal limiting membrane in idiopathic epiretinal membranes. Retina. 2018;38(Suppl 1):S5–S11.CrossRef
40.
go back to reference McCarty DJ, Mukesh BN, Chikani V, Wang JJ, Mitchell P, Taylor HR, McCarty CA. Prevalence and associations of epiretinal membranes in the visual impairment project. Am J Ophthalmol. 2005;140(2):288–94.CrossRef McCarty DJ, Mukesh BN, Chikani V, Wang JJ, Mitchell P, Taylor HR, McCarty CA. Prevalence and associations of epiretinal membranes in the visual impairment project. Am J Ophthalmol. 2005;140(2):288–94.CrossRef
41.
go back to reference Nakamura KM, Diehl NN, Mohney BG. Incidence, ocular findings and systemic associations of ocular Coloboma: a population-based study. Arch Ophthalmol. 2011;129(1):69–74.CrossRef Nakamura KM, Diehl NN, Mohney BG. Incidence, ocular findings and systemic associations of ocular Coloboma: a population-based study. Arch Ophthalmol. 2011;129(1):69–74.CrossRef
Metadata
Title
Ocular manifestations in Gorlin-Goltz syndrome
Authors
Antonietta Moramarco
Ehud Himmelblau
Emanuele Miraglia
Fabiana Mallone
Vincenzo Roberti
Federica Franzone
Chiara Iacovino
Sandra Giustini
Alessandro Lambiase
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2019
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-019-1190-6

Other articles of this Issue 1/2019

Orphanet Journal of Rare Diseases 1/2019 Go to the issue